Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.Rámón Colomer, Belén Lloveras, Sagrario Montero et al.|PubMed|2000Cited by 172
Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast CancerJosé Baselga, Frederico Costa, Hélio Pinczowski et al.|Journal of Clinical Oncology|2012Cited by 163